"Sinovac has received vaccine orders from Brazil, Indonesia, Turkey, Chile and some other countries and regions, and we are making every effort to expand the production capacity," Yin said.

Pearson Liu, director of brand management and public relations of Sinovac, said the company will export semifinished jabs to some countries, and help build local filling and packaging lines in importing countries to improve the production capacity and efficiency.

The company's COVID-19 vaccine exported overseas received warm welcome in destination countries.

On Jan 14, Turkish President Recep Tayyip Erdogan received the COVID-19 vaccine produced by Sinovac.

In Indonesia, the president, cabinet members, as well as influential public figures in the country, received Sinovac's vaccination.

Apart from the four approved vaccines, vaccine candidates under development by other Chinese producers are making steady progress. For instance, the mRNA vaccine developed by Walvax Biotechnology Co Ltd and its partners, is said to be a strong candidate.

Walvax, the only domestic producer of China's self-developed 13-valent pneumococcal polysaccharide conjugate vaccine, said it has three COVID-19 vaccine candidates on its hands. Among them is the mRNA vaccine, which uses a new technology to stimulate the immune system to trigger appropriate responses against the virus.

The mRNA vaccine received approval from the NMPA for clinical trials on June 19, and has already entered phase-II clinical trials. It also has excellent stability in storage at 2-8 C, which means it will be much less demanding during transportation and in terms of storage conditions, compared to similar mRNA vaccines developed by other producers.

The company has started the construction of a manufacturing base with considerable capacity for the mRNA vaccine, which is expected to reach production in a few months.